Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20552773 | 0.93 | LMNA (0.47) | SMN1; SMN2LMNAMAPTL3MBTL1HPGD | |
| SCHEMBL25786634 | 0.90 | LMNA (0.47) | SMN1; SMN2LMNAMAPTL3MBTL1HPGD | |
| SCHEMBL20552904 | 0.87 | MAPT (0.51) | SMN1; SMN2LMNAMAPTL3MBTL1HPGD | |
| SCHEMBL25786650 | 0.85 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAMAPTL3MBTL1HPGD | |
| SCHEMBL25786641 | 0.84 | RAB9A (0.58) | SMN1; SMN2LMNAMAPTNPC1RAB9A | |
| SCHEMBL20552310 | 0.83 | MAPT (0.48) | SMN1; SMN2LMNAMAPTL3MBTL1HPGD | |
| SCHEMBL25786906 | 0.82 | MAPT (0.47) | SMN1; SMN2LMNAMAPTL3MBTL1HPGD | |
| SCHEMBL25787163 | 0.81 | KDM4E (0.52) | SMN1; SMN2LMNAMAPTL3MBTL1HPGD | |
| SCHEMBL20552875 | 0.81 | ABCG2 (0.53) | SMN1; SMN2LMNAMAPTHPGDUSP2 | |
| SCHEMBL20553129 | 0.80 | HPGD (0.61) | SMN1; SMN2LMNAMAPTL3MBTL1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | SMN1; SMN2 3035/4885LMNA 2451/4885MAPT 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.